Table 1

Profile of patients

PatientSexAgeCD4+, cells/mm3HIV-1 RNA*, copies/mlMonths on anti-viral therapyAnti-HIV therapeutics received
1M50361246,70064AZT, ddl, ddC, d4T, 3TC, ABC, IDV, RTV, SQV, APV, DLV
2M383553,70046AZT, ddl, ddC, d4T, 3TC, ABC, IDV, RTV, SQV, APV
3M4410842,61039AZT, ddl, ddC, d4T, 3TC, ABC, IDV, RTV, SQV, APV
4M4056859,99081AZT, ddl, ddC, d4T, 3TC, ABC, IDV, SQV, APV, DLV
5M3829752,76032AZT, ddl, ddC, d4T, 3TC, ABC, IDV, SQV, APV
6M3655415,73034AZT, ddl, ddC, d4T, 3TC, ABC, IDV, SQV, APV
7M453356,54783AZT, ddl, ddC, d4T, 3TC, ABC, IDV, SQV, RTV, APV
  • ddC, zalcitabine; d4T, stavudine; ABC, abacavir (1592U89); APV, amprenavir (VX-478/141W94); DLV, delavirdine; M, male. 

  • * Serum levels of HIV RNA were determined by using a branched-DNA assay.